CU20170029A7 - Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios - Google Patents
Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediariosInfo
- Publication number
- CU20170029A7 CU20170029A7 CUP2017000029A CU20170029A CU20170029A7 CU 20170029 A7 CU20170029 A7 CU 20170029A7 CU P2017000029 A CUP2017000029 A CU P2017000029A CU 20170029 A CU20170029 A CU 20170029A CU 20170029 A7 CU20170029 A7 CU 20170029A7
- Authority
- CU
- Cuba
- Prior art keywords
- composition
- preparation
- disorder
- induction
- useful
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 230000030833 cell death Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 230000006698 induction Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 title 1
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 abstract 1
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185604 | 2014-09-19 | ||
| EP15176903 | 2015-07-15 | ||
| PCT/EP2015/071340 WO2016042084A1 (en) | 2014-09-19 | 2015-09-17 | Benzyl substituted indazoles as bub1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20170029A7 true CU20170029A7 (es) | 2017-08-08 |
Family
ID=54140475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2017000029A CU20170029A7 (es) | 2014-09-19 | 2015-09-17 | Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10350206B2 (ja) |
| EP (1) | EP3194379A1 (ja) |
| JP (1) | JP6664385B2 (ja) |
| KR (1) | KR20170049604A (ja) |
| CN (1) | CN107001331A (ja) |
| AP (1) | AP2017009803A0 (ja) |
| AU (1) | AU2015316796A1 (ja) |
| BR (1) | BR112017005444A2 (ja) |
| CA (1) | CA2961589A1 (ja) |
| CL (1) | CL2017000654A1 (ja) |
| CO (1) | CO2017002532A2 (ja) |
| CR (1) | CR20170100A (ja) |
| CU (1) | CU20170029A7 (ja) |
| DO (1) | DOP2017000078A (ja) |
| EA (1) | EA032401B1 (ja) |
| EC (1) | ECSP17016797A (ja) |
| IL (1) | IL251071A0 (ja) |
| MA (1) | MA39484A (ja) |
| MX (1) | MX2017003664A (ja) |
| NI (1) | NI201700034A (ja) |
| PE (1) | PE20170697A1 (ja) |
| PH (1) | PH12017500509A1 (ja) |
| SG (1) | SG11201702082VA (ja) |
| TN (1) | TN2017000092A1 (ja) |
| TW (1) | TW201615636A (ja) |
| UY (1) | UY36311A (ja) |
| WO (1) | WO2016042084A1 (ja) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| SI2861595T1 (sl) | 2012-06-13 | 2017-04-26 | Incyte Holdings Corporation | Substituirane triciklične spojine kot inhibitorji fgfr |
| ES2657451T3 (es) | 2013-04-19 | 2018-03-05 | Incyte Holdings Corporation | Heterocíclicos bicíclicos como inhibidores del FGFR |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CN105764893A (zh) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| SMT202400446T1 (it) | 2014-02-06 | 2024-11-15 | Nxera Pharma Uk Ltd | Composti aza biciclici come agonisti del recettore muscarinico |
| JP6545199B2 (ja) | 2014-06-17 | 2019-07-17 | バイエル ファーマ アクチエンゲゼルシャフト | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| US10350206B2 (en) | 2014-09-19 | 2019-07-16 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as BUB1 inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| JP7090639B2 (ja) | 2017-04-11 | 2022-06-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | フッ素置換されたインダゾール化合物及びその使用 |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR20210018265A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 고체 형태 및 이의 제조 방법 |
| MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7675711B2 (ja) | 2019-10-14 | 2025-05-13 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての二環式複素環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CR20220285A (es) | 2019-12-04 | 2022-10-27 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5470862A (en) | 1995-02-03 | 1995-11-28 | Ohmeda Pharmaceutical Products Division Inc. | Substituted pyrazolyl compounds and methods employing such compounds |
| US6166027A (en) | 1996-10-14 | 2000-12-26 | Bayer Aktiengesellschaft | Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| WO2003051833A2 (en) | 2001-12-18 | 2003-06-26 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| US7166293B2 (en) | 2002-03-29 | 2007-01-23 | Carlsbad Technology, Inc. | Angiogenesis inhibitors |
| CN1694708A (zh) | 2002-09-10 | 2005-11-09 | 西奥斯股份有限公司 | TGFβ的抑制剂 |
| DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
| WO2007038613A2 (en) | 2005-09-26 | 2007-04-05 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
| EP1709007A1 (en) | 2004-01-22 | 2006-10-11 | Altana Pharma AG | N-4-(6-(heteo)aryl-pyrimidin-4-ylaminophenyl)-benzenesulfonamides as kinase inhibitors |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| CN101765596B (zh) | 2007-05-18 | 2015-04-29 | 拜耳知识产权有限责任公司 | 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂 |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| EP2373626B1 (en) | 2008-12-18 | 2016-08-24 | Nerviano Medical Sciences S.r.l. | Substituted indazole derivatives active as kinase inhibitors |
| WO2011049988A2 (en) | 2009-10-20 | 2011-04-28 | Eiger Biopharmaceuticals, Inc. | Indazoles to treat flaviviridae virus infection |
| NZ715101A (en) | 2009-11-27 | 2017-07-28 | Adverio Pharma Gmbh | Method for producing methyl-{ 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| KR101955691B1 (ko) | 2010-03-30 | 2019-03-07 | 베르선 코포레이션 | 트롬빈 억제제로서의 다중치환된 방향족 화합물 |
| DK2588465T3 (en) | 2010-06-30 | 2017-05-01 | Ironwood Pharmaceuticals Inc | SGC stimulators |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| CA2859779A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| EP2797915B1 (en) | 2011-12-27 | 2016-07-13 | Ironwood Pharmaceuticals, Inc. | 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure |
| WO2013167698A1 (en) | 2012-05-11 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| CA2885645A1 (en) | 2012-09-19 | 2014-03-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| WO2014047662A2 (en) | 2012-09-24 | 2014-03-27 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
| WO2014147144A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
| EP2976336A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CN105164116A (zh) | 2013-03-21 | 2015-12-16 | 拜耳制药股份公司 | 杂芳基取代的吲唑 |
| JP2016522231A (ja) | 2013-06-21 | 2016-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | ジアミノヘテロアリール置換ピラゾール類 |
| CA2916097A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| WO2014202588A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| CN105764893A (zh) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CA2961570A1 (en) | 2014-09-19 | 2016-03-24 | Lars Barfacker | Benzyl substituted indazoles |
| BR112017003548A2 (pt) | 2014-09-19 | 2017-12-12 | Nestec Sa | tratamento de câncer com inibidor de alfa-amilase para animais de estimação |
| DK3447050T3 (da) | 2014-09-19 | 2020-03-09 | Forma Therapeutics Inc | Pyridin-2(1h)-on-quinolinderivater som mutant-isocitrat dehydrogenaseinhibitorer |
| EP3194384A1 (en) | 2014-09-19 | 2017-07-26 | GlaxoSmithKline Intellectual Property Development Limited | Novel soluble guanylate cyclase activators and their use |
| WO2016042081A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| WO2016042080A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 kinase inhibitors |
| US10350206B2 (en) | 2014-09-19 | 2019-07-16 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as BUB1 inhibitors |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
-
2015
- 2015-09-17 US US15/512,494 patent/US10350206B2/en not_active Expired - Fee Related
- 2015-09-17 WO PCT/EP2015/071340 patent/WO2016042084A1/en not_active Ceased
- 2015-09-17 PE PE2017000480A patent/PE20170697A1/es unknown
- 2015-09-17 CU CUP2017000029A patent/CU20170029A7/xx unknown
- 2015-09-17 AP AP2017009803A patent/AP2017009803A0/en unknown
- 2015-09-17 MA MA039484A patent/MA39484A/fr unknown
- 2015-09-17 AU AU2015316796A patent/AU2015316796A1/en not_active Abandoned
- 2015-09-17 SG SG11201702082VA patent/SG11201702082VA/en unknown
- 2015-09-17 CR CR20170100A patent/CR20170100A/es unknown
- 2015-09-17 EA EA201790649A patent/EA032401B1/ru not_active IP Right Cessation
- 2015-09-17 KR KR1020177010425A patent/KR20170049604A/ko not_active Withdrawn
- 2015-09-17 EP EP15763619.2A patent/EP3194379A1/en not_active Withdrawn
- 2015-09-17 CN CN201580062951.4A patent/CN107001331A/zh active Pending
- 2015-09-17 CA CA2961589A patent/CA2961589A1/en not_active Abandoned
- 2015-09-17 BR BR112017005444A patent/BR112017005444A2/pt not_active IP Right Cessation
- 2015-09-17 MX MX2017003664A patent/MX2017003664A/es unknown
- 2015-09-17 JP JP2017514825A patent/JP6664385B2/ja not_active Expired - Fee Related
- 2015-09-17 TN TN2017000092A patent/TN2017000092A1/en unknown
- 2015-09-18 UY UY0001036311A patent/UY36311A/es not_active Application Discontinuation
- 2015-09-18 TW TW104131025A patent/TW201615636A/zh unknown
-
2017
- 2017-03-09 IL IL251071A patent/IL251071A0/en unknown
- 2017-03-16 PH PH12017500509A patent/PH12017500509A1/en unknown
- 2017-03-17 CO CONC2017/0002532A patent/CO2017002532A2/es unknown
- 2017-03-17 NI NI201700034A patent/NI201700034A/es unknown
- 2017-03-17 EC ECIEPI201716797A patent/ECSP17016797A/es unknown
- 2017-03-17 CL CL2017000654A patent/CL2017000654A1/es unknown
- 2017-03-17 DO DO2017000078A patent/DOP2017000078A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10350206B2 (en) | 2019-07-16 |
| UY36311A (es) | 2016-04-29 |
| EA032401B1 (ru) | 2019-05-31 |
| EP3194379A1 (en) | 2017-07-26 |
| CN107001331A (zh) | 2017-08-01 |
| CR20170100A (es) | 2017-04-24 |
| JP6664385B2 (ja) | 2020-03-13 |
| DOP2017000078A (es) | 2017-06-30 |
| TN2017000092A1 (en) | 2018-07-04 |
| SG11201702082VA (en) | 2017-04-27 |
| KR20170049604A (ko) | 2017-05-10 |
| MX2017003664A (es) | 2017-07-13 |
| MA39484A (fr) | 2016-03-24 |
| WO2016042084A1 (en) | 2016-03-24 |
| AU2015316796A1 (en) | 2017-03-30 |
| EA201790649A1 (ru) | 2017-09-29 |
| CL2017000654A1 (es) | 2017-12-11 |
| TW201615636A (zh) | 2016-05-01 |
| IL251071A0 (en) | 2017-04-30 |
| PH12017500509A1 (en) | 2017-08-30 |
| AP2017009803A0 (en) | 2017-03-31 |
| US20170273980A1 (en) | 2017-09-28 |
| CA2961589A1 (en) | 2016-03-24 |
| BR112017005444A2 (pt) | 2018-04-24 |
| CO2017002532A2 (es) | 2017-07-11 |
| ECSP17016797A (es) | 2017-05-31 |
| JP2017530962A (ja) | 2017-10-19 |
| PE20170697A1 (es) | 2017-06-24 |
| NI201700034A (es) | 2017-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170029A7 (es) | Indazoles sustituidos con bencilo en calidad de inhibidores de bub1, útiles para el tratamiento o profilaxis de una enfermedad hiperproliferativa y/o un trastorno que responde a la inducción de la muerte celular, un procedimiento para la preparación de estos compuestos, y compuestos intermediarios | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX380829B (es) | Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa. | |
| MX381160B (es) | Agonistas del receptor de apelina y metodos de uso. | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CL2017003073A1 (es) | Inhibidores de tirosina-cinasas | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| MX384884B (es) | Inhibidores de ret. | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| EA032953B1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX380940B (es) | Compuestos de pirazol y metodo para elaborar y usar los compuestos. | |
| EA201791867A1 (ru) | Бициклические гетероциклы как ингибиторы fgfr4 | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| MY176235A (en) | Compounds that inhibit mcl-1 protein | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| MY189454A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| MX376824B (es) | 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj). | |
| CO2018007221A2 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) | |
| CL2013002446A1 (es) | Compuestos derivados de quinolin-triazolopiridin-etilpirrolidina, como inihibidores de cinasa pim; proceso para su preparacion; compuestos intermediarios; composicion que los comprende, util para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como esclerosis multiple y lupus, y para el tratamiento del cancer. | |
| MX388752B (es) | Composiciones novedosas, usos y métodos para hacerlas. | |
| EA201591889A1 (ru) | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd |